NCT06495749View on ClinicalTrials.gov

Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures

Not yet recruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreatic Cancer Resectable
Trial Locations (2)

310003

First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou

310009

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

OTHER

collaborator

Nanjing Medical University

OTHER

lead

Zhejiang University

OTHER

NCT06495749 - Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures | Biotech Hunter | Biotech Hunter